MEDP vs. ONC: Medpace vs. BeOne Medicines Stock Comparison
How do Medpace (MEDP) and BeOne Medicines (ONC) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Medpace (MEDP) and BeOne Medicines (ONC) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MEDP is classified in Life Sciences Tools & Services while ONC is classified in Biotechnology.
Medpace (MEDP) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | MEDP | ONC |
|---|---|---|
| Name | Medpace Holdings, Inc. | BeOne Medicines Ltd. American Depositary Shares |
| Country/Region | United States | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| GICS Sub-Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 18.27 billion USD | 46.49 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | August 11, 2016 | February 3, 2016 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | MEDP | ONC |
|---|---|---|
| Total Return (1Y) | 13.29% | 30.59% |
| Total Return (3Y, Annualized) | 35.26% | 30.15% |
| Total Return (5Y, Annualized) | 24.49% | 2.48% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | MEDP | ONC |
|---|---|---|
| Volatility (1Y, Annualized) | 44.16% | 35.90% |
| Beta (5Y) | 1.10 | 0.59 |
| Max Drawdown (5Y) | -42.87% | -68.89% |
| Avg. Volume (3M) | 258.39K | 405.29K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | MEDP | ONC |
|---|---|---|
| Sharpe Ratio (1Y) | 0.20 | 0.73 |
| Sortino Ratio (1Y) | 0.26 | 1.15 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Medpace (MEDP) at 117.88% is the standout with ROE above its industry range; BeOne Medicines (ONC) at 18.40% also sits in the top quartile.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
117.88%
- MEDP
- 117.88%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.40%
- Max
- 109.18%
- ONC
- 18.40%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Medpace (MEDP) at 18.24% keeps the most of each sales dollar — above its industry’s net margin range — and BeOne Medicines (ONC) at 13.86% also retains a top-quartile share.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.24%
- MEDP
- 18.24%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.86%
- Max
- 18.05%
- ONC
- 13.86%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Medpace (MEDP) at 23.12% and BeOne Medicines (ONC) at 22.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.12%
- Max
- 83.12%
- MEDP
- 23.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.15%
- Max
- 83.12%
- ONC
- 22.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | MEDP | ONC |
|---|---|---|
| ROE (TTM) | 117.88% | 18.40% |
| ROA (TTM) | 18.71% | 8.42% |
| Net Margin (TTM) | 18.24% | 13.86% |
| Operating Margin (TTM) | 23.12% | 22.15% |
| Gross Margin (TTM) | 72.24% | 89.39% |
Growth
Revenue Growth
Both Medpace (MEDP) at 19.97% and BeOne Medicines (ONC) at 40.23% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Medpace (MEDP) reports EPS growth of 20.98%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.
Growth Metrics
| Metric | MEDP | ONC |
|---|---|---|
| Revenue Growth (YoY) | 19.97% | 40.23% |
| Revenue Growth (3Y CAGR) | 20.12% | 55.69% |
| EPS Growth (YoY) | 20.98% | -- |
| EPS Growth (3Y CAGR) | 28.04% | -- |
Financial Strength
Current Ratio (MRQ)
BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while Medpace (MEDP) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MEDP.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MEDP
- 0.83
- Min
- 0.10
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ONC
- 3.55
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Medpace (MEDP) at 0.29 and BeOne Medicines (ONC) at 0.35 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.29
- Max
- 1.42
- Q3
- 0.65
- MEDP
- 0.29
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.42
- Q3
- 0.65
- ONC
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | MEDP | ONC |
|---|---|---|
| Current Ratio (MRQ) | 0.83 | 3.55 |
| Debt / Equity (MRQ) | 0.29 | 0.35 |
| Net Debt / EBITDA | -0.84 | -2.80 |
Dividends
Dividend Yield (TTM)
Neither Medpace (MEDP) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MEDP
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Medpace (MEDP) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MEDP
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | MEDP | ONC |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Medpace (MEDP) at 36.26 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.26
- Max
- 85.34
- Q3
- 43.46
- MEDP
- 36.26
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.17
- Max
- 85.34
- ONC
- 52.17
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Medpace (MEDP) at 6.44 and BeOne Medicines (ONC) at 7.04 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.44
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- MEDP
- 6.44
- Q1
- 3.01
- Min
- 0.01
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ONC
- 7.04
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both look rich against book: BeOne Medicines (ONC) at 7.98 sits in the upper P/B ratio quartile, and Medpace (MEDP) at 31.23 prices even higher, above its industry range.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.23
- MEDP
- 31.23
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.98
- Max
- 13.53
- ONC
- 7.98
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | MEDP | ONC |
|---|---|---|
| P/E Ratio (TTM) | 36.26 | 52.17 |
| P/S Ratio (TTM) | 6.44 | 7.04 |
| P/B Ratio (MRQ) | 31.23 | 7.98 |
| Free Cash Flow Yield (TTM) | 2.72% | 2.21% |